Citations

Showing 10 of 108094 citations.

The role of whole‐brain radiation therapy in patients with cerebral metastases
Trifiletti, Daniel M. , Brown, Paul D. , Trifiletti, Daniel M

Mayo Clinic

Cancer | March 31, 2018 | Volume: 124 | Issue: 10 | Pages: 2072-2074

10.1002/cncr.31352 | PMID 29603127 Get It

In general, the role of whole‐brain radiation therapy (WBRT) in patients with cerebral metastases is evolving in favor of focused, radiosurgery‐alone approaches. Despite this, there still is a role for WBRT in many patients, and improvements in patient selection, advanced radiotherapy techniques, and novel medical and cellular therapies will continue to improve the therapeutic ratio of WBRT.
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Pinto, Navin , DuBois, Steven G. , Marachelian, Araz , Diede, Scott J. , Taraseviciute, Agne, Bender, Julia Glade , Groshen, Susan , Haas‐Kogan, Daphne A. , Kang, Min H. , Irwin, Meredith S. , Macy, Margaret E. , Villablanca, Judith G. , Reid, Joel M. , Irwin, Meredith S , Macy, Margaret E , Villablanca, Judith G , Tsao-Wei, Denice D , Reynolds, C. Patrick , Matthay, Katherine K. , Park, Julie R. , Glade-Bender, Julia

Mayo Clinic

Pediatric Blood & Cancer | March 31, 2018 | Volume: 65 | Issue: 7 | Pages: No page available

10.1002/pbc.27023 | PMID 29603591 Get It

AbstractBackgroundVorinostat combined with retinoids produces additive antitumor effects in preclinical studies of neuroblastoma. Higher systemic exposures of vorinostat than achieved in pediatric phase I trials with continuous daily dosing are necessary for in vivo increased histone acetylation and cytotoxic activity. We conducted a phase I trial in children with relapsed/refractory neuroblastoma to determine the maximum tolerated dose (MTD) of vorinostat on an interrupted schedule, escalating beyond the previously identified pediatric MTD.MethodsIsotretinoin (cis‐13‐retinoic acid) 80 mg/m2/dose was administered by mouth twice daily on days 1–14 in combination with escalating doses of daily vorinostat up to 430 mg/m2/dose (days 1–4; 8–11) in each 28‐day cycle using the standard 3 + 3 design. Vorinostat pharmacokinetic testing and histone acetylation assays were performed.ResultsTwenty‐nine patients with refractory or relapsed neuroblastoma were enrolled and 28 were evaluable for dose escalation decisions. Median number of cycles completed was two (range 1–15); 11 patients received four or more cycles. Three patients experienced cycle 1 dose‐limiting toxicities. A total of 18 patients experienced grade 3/4 toxicities related to study therapy. The maximum intended dose of vorinostat (430 mg/m2/day, days 1–4; 8–11) was tolerable and led to increased histone acetylation in surrogate tissues when compared to lower doses of vorinostat (P = 0.009). No objective responses were seen.ConclusionsIncreased dose vorinostat (430 mg/m2/day) on an interrupted schedule is tolerable in combination with isotretinoin. This dose led to increased vorinostat exposures and demonstrated increased histone acetylation. Prolonged stable disease in patients with minimal residual disease warrants further investigation.
Post‐acute care use after major head and neck oncologic surgery with microvascular reconstruction
Parhar, Harman S. , Durham, J. Scott, Anderson, Donald W., Hayden, Richard E. , Prisman, Eitan , Chang, Brent A. , Prisman, Eitan

Mayo Clinic

The Laryngoscope | March 30, 2018 | Volume: 128 | Issue: 11 | Pages: 2532-2538

10.1002/lary.27190 | PMID 29602261 Get It

ObjectivesPost‐acute care (PAC) centers, such as skilled nursing facilities, unskilled nursing facilities, lower acuity hospitals, and rehabilitation centers, serve to optimize recovery after acute care hospitalization. We aimed to identify factors associated with PAC utilization among patients undergoing head and neck cancer surgery with microvascular reconstruction because it may be helpful for patient decision making, discharge planning, and resource allocation.MethodsRetrospective linked analysis of the 2011 to 2015 National Surgical Quality Improvement Program. Eligible patients were identified and stratified by discharge disposition (home or PAC) after their postoperative acute‐care hospitalization. After an initial univariate screen of demographic and clinical variables, a multivariable logistic regression analysis was performed modelling discharge to PAC.ResultsOf the 1,652 identified patients, 261 (15.8%) were discharged to PAC. Those admitted to PAC were older, had a higher burden of comorbidity, and were more likely to be functionally dependent. They also had longer surgeries, longer hospitalizations, higher rates of reoperation, and higher rates of postoperative complications. After multivariate analysis, factors independently associated with PAC discharge included increasing age (odds ratio [OR] 2.12 per 10‐year increase; 95% confidence interval [CI], 1.81–2.48), active smoking status (odds ratio (OR) 1.61; 95% confidence interval (CI), 1.13–2.29), prolonged hospitalization (OR 1.04; 95% CI, 1.02–1.07), and postoperative pulmonary complications (OR 2.02; 95% CI, 1.36–2.99).ConclusionOf the patients undergoing surgery for head and neck cancers with microvascular reconstruction, 15.8% are discharged to PAC. Age, active smoking status, prolonged hospitalization, and postoperative pulmonary complications (vs. comorbidity, functional status, or primary tumor site) are independently associated with discharge to PAC.Level of EvidenceLevel 2c. Laryngoscope, 2532–2538, 2018
Surgical Resection of Intramedullary Epidermoid Cyst: 2-Dimensional Operative Video
Sorenson, Thomas J. , Sorenson, Thomas, Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | March 30, 2018 | Volume: 15 | Issue: 6 | Pages: 728-729

10.1093/ons/opy067 | PMID 29618113 Get It

Abstract Intramedullary epidermoid cysts are extremely rare lesions. Preoperative diagnosis can be challenging due to non-specific imaging futures. We illustrate the case of a 32-year-old man who presented with a symptomatic intramedullary mass, which at surgery proved to be an epidermoid cyst. The spinal cord was decompressed by removing the pearl-white keratin material, although the capsule, which was tenaciously adherent to the surrounding spinal cord parenchyma, was only partially removed. In this video, we illustrate the salient surgical points for the resection of this very unusual intramedullary lesion.
Subspine Impingement: Technique for Arthroscopic Decompression
Putnam, Jill A., Patel, Karan A. , Hartigan, David E. , Patel, Karan

Mayo Clinic

Techniques in Orthopaedics | March 30, 2018 | Volume: 34 | Issue: 2 | Pages: 125-128

10.1097/bto.0000000000000306 Get It

The anterior inferior iliac spine (AIIS) is a newly recognized etiology of extra-articular hip impingement. The purpose of this article is to describe an arthroscopic technique for AIIS decompression causing extra-articular hip impingement. Arthroscopic decompression of subspine impingement is a novel procedure that can be used to successfully relieve hip pain and improve hip function and range of motion cause by AIIS impingement.
Spontaneous occult intracranial hypotension precipitating life-threatening cerebral venous thrombosis: case report
Perry, Avital , Graffeo, Christopher S. , Brinjikji, Waleed , Copeland, William R., Link, Michael J., Rabinstein, Alejandro A. , Link, Michael J.

Mayo Clinic

Journal of Neurosurgery: Spine | March 30, 2018 | Volume: 28 | Issue: 6 | Pages: 669-678

10.3171/2017.10.spine17806 | PMID 29600909 Get It

Spontaneous intracranial hypotension (SIH) is an uncommon headache etiology, typically attributable to an unprovoked occult spinal CSF leak. Although frequently benign, serious complications may occur, including cerebral venous thrombosis (CVT). The objective of this study was to examine a highly complicated case of CVT attributable to SIH as a lens for understanding the heterogeneous literature on this rare complication, and to provide useful, evidence-based, preliminary clinical recommendations. A 43-year-old man presented with 1 week of headache, dizziness, and nausea, which precipitously evolved to hemiplegia. CT venography confirmed CVT, and therapeutic heparin was initiated. He suffered a generalized seizure due to left parietal hemorrhage, which subsequently expanded. He developed signs of mass effect and herniation, heparin was discontinued, and he was taken to the operating room for clot evacuation and external ventricular drain placement. Intraoperatively, the dura was deflated, suggesting underlying SIH. Ventral T-1 CSF leak was identified, which failed multiple epidural blood patches and required primary repair. The patient ultimately made a complete recovery. Systematic review identified 29 publications describing 36 cases of SIH-associated CVT. Among 31 patients for whom long-term neurological outcome was reported, 25 (81%) recovered completely. Underlying coagulopathy/risk factors were identified in 11 patients (31%). CVT is a rare and potentially lethal sequela occurring in 2% of SIH cases. Awareness of the condition is poor, risking morbid complications. Evaluation and treatment should be directed toward identification and treatment of occult CSF leaks. Encouragingly, good neurological outcomes can be achieved through vigilant multidisciplinary neurosurgical and neurocritical care.
Frontline Science: Characterization of a novel mouse strain expressing human Siglec-8 only on eosinophils
O’Sullivan, Jeremy A. , Wei, Yadong , Carroll, Daniela J., Moreno‐Vinasco, Liliana, Cao, Yun , Zhang, Fengrui , Lee, James J. , Zhu, Zhou , Bochner, Bruce S.

Mayo Clinic

Journal of Leukocyte Biology | March 30, 2018 | Volume: 104 | Issue: 1 | Pages: 11-19

10.1002/jlb.2hi0917-391r | PMID 29601103 Get It

Abstract Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a human cell surface protein expressed exclusively on eosinophils, mast cells, and basophils that, when engaged, induces eosinophil apoptosis and inhibits mast cell mediator release. This makes Siglec-8 a promising therapeutic target to treat diseases involving these cell types. However, preclinical studies of Siglec-8 targeting in vivo are lacking because this protein is only found in humans, apes, and some monkeys. Therefore, we have developed a mouse strain in which SIGLEC8 transcription is activated by Cre recombinase and have crossed this mouse with the eoCre mouse to achieve eosinophil-specific expression. We confirmed that Siglec-8 is expressed exclusively on the surface of mature eosinophils in multiple tissues at levels comparable to those on human blood eosinophils. Following ovalbumin sensitization and airway challenge, Siglec-8 knock-in mice generated a pattern of allergic lung inflammation indistinguishable from that of littermate controls, suggesting that Siglec-8 expression within the eosinophil compartment does not alter allergic eosinophilic inflammation. Using bone marrow from these mice, we demonstrated that, during maturation, Siglec-8 expression occurs well before the late eosinophil developmental marker C-C motif chemokine receptor 3, consistent with eoCre expression. Antibody ligation of the receptor induces Siglec-8 endocytosis and alters the phosphotyrosine profile of these cells, indicative of productive signaling. Finally, we demonstrated that mouse eosinophils expressing Siglec-8 undergo cell death when the receptor is engaged, further evidence that Siglec-8 is functional on these cells. These mice should prove useful to investigate Siglec-8 biology and targeting in vivo in a variety of eosinophilic disease models. We have developed a novel eosinophil-specific Siglec-8 knock-in mouse strain that facilitates the in vivo study of Siglec-8 targeting and biology.
Metastatic Spinal Cord Compression and Steroid Treatment
Kumar, Abhishek , Weber, Michael H. , Gokaslan, Ziya L. , Wolinsky, Jean‐Paul , Schmidt, Meic H. , Rhines, Laurence D. , Fehlings, Michael G. , Laufer, Ilya , Sciubba, Daniel M. , Sundaresan, Narayan, Verlaan, Jorrit‐Jan , Sahgal, Arjun , Chou, Dean , Fisher, Charles G. , Fehlings, Michael G , Clarke, Michelle J.

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | March 30, 2018 | Volume: 30 | Issue: 4 | Pages: 156-163

10.1097/bsd.0000000000000528 | PMID 28437329 Get It

Study Design: Systematic review. Objectives: We conducted a systematic review of the literature to answer the following questions regarding the use of steroid therapy in metastatic spinal cord compression (MSCC): 1. In cases of MSCC, what is the effect of steroid administration before definitive radiotherapy or surgery on ambulatory status, bowel and bladder function and survival? 2. What steroid dosing regimens are associated with the best outcomes concerning neurological symptoms and complication prevention in cases of MSCC? Summary of Background Data: Currently, there is significant variation in the initial bolus dose, daily maintenance dose and duration of treatment when steroids are used as a bridge to definitive therapy for MSCC. Methods: A literature search following PRISMA guidelines was conducted in June 2016, using Medline via Ovid SP, Medline via PubMed, Embase, Biosis Previews and the Cochrane Library. Search terms used in each database varied slightly to optimize results. All generic steroid formulations were included along with spinal cord compression or myelopathy combined with metastatic or malignant tumors. Papers discussing acute traumatic causes of spinal cord compression were excluded, as were papers discussing cord compression from nonmetastatic tumors or epidural lipomatosis. Subjects were limited to adult humans undergoing definitive treatment with radiotherapy or surgery. Results: Of the 309 papers retrieved, 66 full text studies were reviewed and 6 papers were found to address the stated questions. Conclusions: There is a paucity of high quality literature evaluating the use of steroids in MSCC. On the basis of the evidence available an initial 10 mg intravenous bolus of dexamethasone followed by 16 mg PO QD has been associated with fewer complications compared with 100 mg bolus and 96 mg QD. Weaning of steroids should occur rapidly after definitive treatment. Risk of gastric bleeding or perforation can be managed with the routine use of proton-pump inhibitors. Level of Evidence: Level IIIa.
Complications, Readmissions, and Revisions for Spine Procedures Performed by Orthopedic Surgeons Versus Neurosurgeons
Norden, Justin, Veeravagu, Anand , Swinney, Christian, Cole, Tyler S. , McCutcheon, Brandon A., Mabud, Tarub S. , Ratliff, John K.

Mayo Clinic

Clinical Spine Surgery: A Spine Publication | March 30, 2018 | Volume: 30 | Issue: 10 | Pages: E1376-E1381

10.1097/bsd.0000000000000426 | PMID 27623297 Get It

Study Design: Retrospective database analysis. Objective: To examine the impact of training pathway, either neurosurgical or orthopedic, on complications, readmissions, and revisions in spine surgery. Summary of Background Data: Training pathway has been shown to have an impact on outcomes in various surgical subspecialties. Although training pathway has not been shown to have a significant impact on spine surgery outcomes in the perioperative period, long-term results are unknown. Materials and Methods: A retrospective analysis of 197,682 patients receiving 1 of 3 common spine surgeries [lumbar laminectomy, lumbar fusion, and anterior cervical discectomy and fusion (ACDF)] between 2006 and 2010 was conducted. Patient data were obtained from a large claims database. Postoperative adverse effects, all-cause readmission, revision surgery rates, and intermediary payments in these cohorts of patients were compared between spine surgeons with either neurosurgical or orthopedic backgrounds. Results: Patient demographics, hospital-stay characteristics, and medical comorbidities were similar between neurosurgeons and orthopedic surgeons. The risks of surgical complications, all-cause readmission, and revision surgery were also similar between neurosurgeons and orthopedic surgeons across all procedure types assessed, with several minor exceptions: neurosurgeons had marginally higher odds of any complication for lumbar fusions [odds ratio (OR) 1.14; 95% confidence interval (CI), 1.09–1.20] and ACDFs (OR, 1.09; 95% CI, 1.04–1.15). Neurosurgeons also had slightly higher rates of revision surgery for concurrent lumbar laminectomy with fusion (OR, 1.14; 95% CI, 1.08–1.22), and ACDFs (OR, 1.20; 95% CI, 1.14–1.28). No associations between surgeon type and any particular complication were consistently observed for all procedure groups. There were also no associations between surgeon type and 30-day all-cause readmission. Median total intermediary payments were somewhat higher for neurosurgery patients for all procedure groups assessed. Conclusions: Few significant associations between surgeon type and patient outcomes exist in the context of spine surgery. Those which do are small and unlikely to be clinically meaningful. Level of Evidence: Level 3.
Non-tuberculous mycobacterial pulmonary infections
Chalmers, James D. , Aksamit, Timothy R. , Carvalho, Anna Cristina Calçada , Rendón, Adrián , Franco, Isaac Cano, Chalmers, James D

Mayo Clinic

Pulmonology | March 30, 2018 | Volume: 24 | Issue: 2 | Pages: 120-131

10.1016/j.pulmoe.2017.12.005 Get It